Navigation Links
Pharmos Corporation Reports 2011 Second Quarter Results
Date:8/8/2011

uction of various facility related expenses as the Company continued to reduce overall facility costs.

General and administrative expenses for the first half of 2011 decreased by $86,046, or 13%, from $639,806 in 2010 to $553,760 in 2011. The primary reductions were a $47,000 reduction in consultant and professional fees, a $31,000 reduction in salaries and benefits and an $8,000 reduction in various facility related expenses. Accounting fees have decreased as there were higher accounting fees related to the filing of a Regulation statement on Form S-1 in 2010. Also professional fees have decreased as there were business development fees in 2010 related to a possible reverse merger candidate which eventually was not pursued. The decrease in payroll costs in 2011 reflects lower stock compensation costs and the elimination of an administrative position in 2010. The decrease in the facility related expenses were a combination of all expense items and overall was not a significant reduction.

About Pharmos Corporation Pharmos discovers and develops novel therapeutics to treat a range of indications, including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders.  The Company's lead products are the two enantiomers of tofisopam. S-tofisopam (levotofisopam) is being evaluated for the treatment of gout, but has not yet entered clinical trials in the US. R-tofisopam (dextofisopam) has been developed through Phase 2b for IBS in the US. There is a large unmet need for new therapeutic alternatives for the treatment of IBS, a chronic and sometimes debilitating condition that affects roughly 10-15% of U.S. adults, primarily women. Pharmos is seeking a partnership with another pharmaceutical company to further develop this promising compound for IBS. The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds, with
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
2. Pharmos Issues Business Update on Dextofisopam Trial and Financing
3. Pharmos Corporation Reports 2009 Third Quarter Results
4. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
5. Pharmos Corporation Reports 2010 Third Quarter Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 Sanomedics ... "Company"), a medical technology company that focuses on ... today that the Company,s subsidiary, Thermomedics, Inc. , ... Specialty and Government Sales. LeBel will be reporting ... and Sales, and will be responsible for supporting ...
(Date:3/4/2015)... , March 4, 2015 Perrigo Company plc ... Chairman, President and CEO Joseph C. Papa will ... ET on Wednesday, March 11, 2015 at the Loews Miami ... parties can access the presentation webcast at http://perrigo.investorroom.com/events-webcasts . ... home remedies in 1887, Perrigo Company plc, headquartered in ...
(Date:3/3/2015)... 3, 2015 Actavis plc (NYSE: ... offering of $21 billion aggregate principal amount of senior ... offering to be issued by its indirect wholly-owned subsidiary, ... other subsidiaries (the "Notes"), as follows: Logo ... Notes* , $500,000,000 , Due 2016 , ...
Breaking Medicine Technology:Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 2Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 3Perrigo Company To Present At The 2015 Barclays Global Healthcare Conference 2Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 2Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 3Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 4Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 6Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 7Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 8Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 9Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 10
(Date:3/4/2015)... SIGVARIS proved innovative when they ... compression therapy collection designed exclusively for men. Building ... is proud to announce the launch of three additional ... from a unique, extremely fine synthetic fiber, MIDTOWN MICROFIBER ... and thigh-highs offer a tailored look that is perfect ...
(Date:3/4/2015)... March 04, 2015 The Alliance ... leaders for its upcoming fifth annual Advanced Therapies ... France. The event this year will feature five ... 20 of the field’s leading companies and organizations. ... top executives and clinical researchers from the advanced ...
(Date:3/4/2015)... 04, 2015 Jeannie Mai, TV personality, fashion ... graces the cover of the print publication. Mai embraces the ... organic when shopping for clothes and personal care products. In ... about her commitment to an organic diet. She mentions, “Having ... only in gymnastics, but also now as I’m a full ...
(Date:3/4/2015)... Francisco, CA (PRWEB) March 04, 2015 ... solutions have been selected by Chase Brexton Health ... company announced today. , Chase Brexton provides comprehensive ... more than 30,000 patients across seven clinics in ... early adopters of electronic medical records, the organization ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 A new ... showing promise in terms of extending life. Studies ... that this new dieting routine can help extend life ... production clearly has long term benefits, many suffering from ... a quicker substitute is necessary. As an alternative to ...
Breaking Medicine News(10 mins):Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3
... treatment for sickle cell disease developed at the Los ... 3 clinical trials, David I. Meyer, PhD, LA BioMed ... U.S. have begun administering the sickle cell treatment developed ... LA BioMed and licensed to Emmaus Medical, Inc. The ...
... & Science University Knight Cancer Institute researchers found that the ... acts independently of the HER-2 gene, known to be a ... gene could ultimately help fine-tune a patient,s treatment and enable ... The study, published online this month by Breast Cancer ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, July ... airborne fungus that can cause life-threatening illness -- is an ... Thursday. While C. gattii infections are rare ... they can be severe and even fatal, researchers at the ...
... of the Division of Allergy and Immunology at ... to extend funding of his long-standing investigation into ... the award from the National Institute of Allergy ... record of research accomplishment." Eosinophilic disorders ...
... Hepatitis B virus (HBV) and hepatitis C virus (HCV) ... according to a new study in Gastroenterology , ... Institute. In this study, doctors found that anesthesia contamination ... infection. Efforts are needed to better educate ...
... Calif.) A total joint replacement registry based on ... quality of care, cost-effectiveness and research, according to a ... Clinical Orthopedics and Related Research , a journal ... Kaiser Permanente,s Total Joint Replacement Registry the nation,s ...
Cached Medicine News:Health News:Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial 2Health News:OHSU Knight Cancer Institute researchers isolate importance of gene in breast cancer prognosis 2Health News:Dangerous Fungus Now Endemic in Pacific Northwest: CDC 2Health News:Dangerous Fungus Now Endemic in Pacific Northwest: CDC 3Health News:Doctor at Cincinnati Children's receives prestigious NIH MERIT Award 2Health News:Misuse of anesthesia could cause hepatitis virus transmission 2Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: